Equibles does not estimate personal net worth.
Get an email with a short summary when Eton Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ETON alertsEton Pharmaceuticals, Inc. reported in an 8-K filed March 1, 2023 that David Krempa was appointed Chief Business Officer, effective March 1, 2023. The proxy statement of Eton Pharmaceuticals, Inc. reports total compensation of $719,080 for David Krempa in fiscal 2023, including a base salary of $372,583. Disclosed compensation is on record for 2 fiscal years. David Krempa has spoken on 11 earnings calls across 1 company, most recently for Eton Pharmaceuticals, Inc. on November 5, 2026. Eton Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Eton Pharmaceuticals, Inc. includes Sean Brynjelsen (CEO and Board Member), Norbert G. Riedel (Chairman), James Gruber (CFO) and 5 others.
“Effective March 1, 2023, Eton Pharmaceuticals, Inc. (“Eton" or the “Company") has appointed David Krempa to the position of Chief Business Officer.”
“This afternoon, we issued our earnings release, which is available on our website, eatonpharma.com. Joining me today are Sean Brynjelsen, our CEO, Ipek Trinkas, our Chief Commercial Officer, and Judy Matthews, our Chief Financial Officer.”
“This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, eatonpharma.com. Joining me on our call today, we have Sean Brinjelsen, our CEO, Ipek Trinkas, our Chief Commercial Officer, and Judy Matthews, our Chief Financial Officer.”
“This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call.”
“This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, eatonfarmer.com. Joining me on our call today, we have Sean Brangelson, our CEO, James Gruber, our CFO, and Ipek Trinkas, our Chief Commercial Officer.”
“This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, etonpharma.com. Joining me on our call today, we have Sean Brynjelsen, our CEO; and James Gruber, our CFO.”
Proxy statement
Start not stated–present
Last confirmed April 24, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | $372,583 | $719,080 |
| 2022 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | $307,875 | $916,805 |
